Total Funding
95
76
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
350
Grail is a healthcare company that develops pan-cancer screening tests designed to detect cancers at an early stage.
George Golumbeski: PresidentPast Role: Celgene, Executive Vice President of Business Development
Charlotte Arnold: Head of Corporate CommunicationsPast Role: Gyroscope Therapeutics, Vice President, Corporate Affairs
Illumina
About the Company
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.
The company was founded in 2016 by Alex
Aravanis and Jeff Huber in Menlo Park, California.
